Case todayNot read todayThesis-Break EngineThe case · mixed · Nov 19, 2026Own PTIX if PTIX is not yet a commercial drug company; it is a financing- and evidence-dependent biotech option whose value turns on whether its stress-related neuropsychiatric pipeline can produce credible validation before cash burn and dilution.5 conditions2 strengthening · 1 holding · 2 weakeningNext resultsNot scheduledNo date filed yet

PTIX at a glance

The past year

Chart

−77.4% $0.46, close Nov 17

From the highest close
−79.8%
Vs the 200-day average
−19.6%
Nov 14, 2025Daily close, Protagenic Therapeutics, Inc.\newNov 17, 2026

Short interest

History

12,907 shares

Since the last report
−0.3%
Days to cover
6.6 days
Settled
Oct 30, 2026

Insider buying, 7 days

Filings

None filed this week

Form 4s filed
Nov 13 – Nov 19

Understand the Business

Why the Stock Moved

Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.

PTIX price history

Latest price$0.42Today−$0.04 (-8.30%)
PTIX -44.92%S&P 500 -5.00%Since first plotted close
4 hours

Loading recent earnings…

Investment thesis

What must happen next

5 MATERIAL PROPOSITIONS
  • PTIX’s business value depends on its stress-related neuropsychiatric research producing external validation, because there is not yet a commercial customer or product-demand engine to underwrite the company.WeakeningMateriality: High

    GAAP annual revenue was $0.0 in FY2026, confirming PTIX is still pre-commercial. If validation arrives, the equity can be valued as a drug-development option; if it does not, the company remains a cash-burning shell around uncertain science.

    Watch: A disclosed failure of the lead neuropsychiatric program to show a credible biological or clinical signal would remove the core source of option value.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP annual revenue was $0.0 in FY2026, confirming PTIX is still pre-commercial.

    Open source ↗
  • The company must maintain enough funding runway to reach a pipeline value-inflection event; otherwise financing mechanics, not drug science, will determine shareholder outcomes.HoldingMateriality: High

    Cash was $1.509 million at FY2026 year-end, up from $14,531 at FY2025 year-end. Adequate runway preserves upside to future data or partnerships, while inadequate runway can force punitive dilution or restructuring before the thesis can be tested.

    Watch: A move into more expensive internally funded clinical work without a partner or financing would shorten runway before data can arrive.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Cash was $1.509 million at FY2026 year-end, up from $14,531 at FY2025 year-end.

    Open source ↗
  • Until PTIX has validating data or a partner, management must keep the development model lean and variable rather than building a fixed-cost organization that its balance sheet cannot support.WeakeningMateriality: Medium

    GAAP annual operating cash flow was negative $2.807 million in FY2026. Expense discipline extends the time available for a scientific catalyst; fixed-cost escalation would increase dilution risk even if the pipeline remains scientifically plausible.

    Watch: Launching a larger internally funded trial without non-dilutive capital would make the cost base less flexible.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP annual operating cash flow was negative $2.807 million in FY2026.

    Open source ↗
  • PTIX’s improved balance sheet must translate into continued fundability; if creditors or new investors regain control of the economics, common shareholders lose the benefit of any pipeline progress.StrengtheningMateriality: Medium

    Stockholders’ equity was positive $2.619 million at FY2026 year-end after being negative $4.953 million at FY2025 year-end. A fundable capital structure lets shareholders participate in successful data; a stressed structure can transfer value to financiers through discounts, warrants, or senior claims.

    Watch: Issuing deeply discounted equity, convertible debt, or warrant-heavy financing would indicate the capital structure is still extracting value from common shareholders.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Stockholders’ equity was positive $2.619 million at FY2026 year-end after being negative $4.953 million at FY2025 year-end.

    Open source ↗
  • Investors should not treat reported profitability as evidence of an operating engine unless it is accompanied by revenue or operating-profit improvement from the drug-development business.StrengtheningMateriality: Medium

    GAAP annual operating income was negative $4.504 million in FY2026 despite GAAP annual net income of positive $1.368 million. If profitability is non-operating or episodic, valuation should remain anchored to pipeline probability and runway rather than earnings power.

    Watch: A licensing or collaboration agreement with recurring economics would begin to create operating validation rather than one-time accounting gains.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP annual operating income was negative $4.504 million in FY2026 despite GAAP annual net income of positive $1.368 million.

    Open source ↗
Full investment case & evidence

Loading the original research archive…

Original research

PTIX’s business value depends on its stress-related neuropsychiatric research producing external validation, because there is not yet a commercial customer or product-demand engine to underwrite the company. If validation arrives, the equity can be valued as a drug-development option; if it does not, the company remains a cash-burning shell around uncertain science.

The company must maintain enough funding runway to reach a pipeline value-inflection event; otherwise financing mechanics, not drug science, will determine shareholder outcomes. Adequate runway preserves upside to future data or partnerships, while inadequate runway can force punitive dilution or restructuring before the thesis can be tested.

Until PTIX has validating data or a partner, management must keep the development model lean and variable rather than building a fixed-cost organization that its balance sheet cannot support. Expense discipline extends the time available for a scientific catalyst; fixed-cost escalation would increase dilution risk even if the pipeline remains scientifically plausible.

PTIX’s improved balance sheet must translate into continued fundability; if creditors or new investors regain control of the economics, common shareholders lose the benefit of any pipeline progress. A fundable capital structure lets shareholders participate in successful data; a stressed structure can transfer value to financiers through discounts, warrants, or senior claims.

Investors should not treat reported profitability as evidence of an operating engine unless it is accompanied by revenue or operating-profit improvement from the drug-development business. If profitability is non-operating or episodic, valuation should remain anchored to pipeline probability and runway rather than earnings power.

All standing thesis claims
Original report summary

PTIX is not yet a commercial drug company; it is a financing- and evidence-dependent biotech option whose value turns on whether its stress-related neuropsychiatric pipeline can produce credible validation before cash burn and dilution.

Evidence assessed Nov 19, 2026. Expand each conclusion for its evidence and what would change it. Thesis evidence—not a buy or sell recommendation.

Bull case and bear case

Bull case and bear case for Protagenic Therapeutics, Inc.\new

Where the evidence on Protagenic Therapeutics, Inc.\new disagrees: Mixed on the latest evidence (Nov 19, 2026). Of its 5 thesis points, 2 strengthening, 1 holding and 2 weakening.

Bull case: what the evidence supports

  • The company must maintain enough funding runway to reach a pipeline value-inflection event; otherwise financing mechanics, not drug science, will determine shareholder outcomes.

    sec.gov ↗

  • PTIX’s improved balance sheet must translate into continued fundability; if creditors or new investors regain control of the economics, common shareholders lose the benefit of any pipeline progress.

    sec.gov ↗

  • Investors should not treat reported profitability as evidence of an operating engine unless it is accompanied by revenue or operating-profit improvement from the drug-development business.

    sec.gov ↗

Bear case: what the evidence questions

  • PTIX’s business value depends on its stress-related neuropsychiatric research producing external validation, because there is not yet a commercial customer or product-demand engine to underwrite the company.

    sec.gov ↗

  • Until PTIX has validating data or a partner, management must keep the development model lean and variable rather than building a fixed-cost organization that its balance sheet cannot support.

    sec.gov ↗

Thesis-Break Engine

Thesis-break watch · Protagenic Therapeutics, Inc.\new

12 mo agonow
Trailing daily price. No thesis break has crossed here, so there is no break base rate to project.

No break has crossed Protagenic Therapeutics, Inc.\new’s thesis. Its break conditions are checked against every new filing as it lands.

How the Thesis-Break Engine works →Historical outcomes are measured against the market after past breaks of the same kind, across all companies. Not a prediction.

MARKET + FINANCIAL SNAPSHOT

The numbers behind the thesis

Sourced from filings and market data

What Changed

  1. Mixed
    Entered a material definitive agreement.

    Protagenic Therapeutics, Inc.\new filed an SEC 8-K on 2026-11-17: Entered a material definitive agreement. It is a dated development that tests the current thesis.

  2. Mixed
    Entered a material definitive agreement.

    Protagenic Therapeutics, Inc.\new filed an SEC 8-K on 2026-11-06: Entered a material definitive agreement. It is a dated development that tests the current thesis.

  3. Mixed
    Regulation FD disclosure.

    Protagenic Therapeutics, Inc.\new filed an SEC 8-K on 2026-08-20: Regulation FD disclosure. It is a dated development that tests the current thesis.

Risks / falsifiers

What could break the thesis

  • A disclosed failure of the lead neuropsychiatric program to show a credible biological or clinical signal would remove the core source of option value.
  • A move into more expensive internally funded clinical work without a partner or financing would shorten runway before data can arrive.
  • Launching a larger internally funded trial without non-dilutive capital would make the cost base less flexible.
  • Issuing deeply discounted equity, convertible debt, or warrant-heavy financing would indicate the capital structure is still extracting value from common shareholders.
  • A licensing or collaboration agreement with recurring economics would begin to create operating validation rather than one-time accounting gains.

PTIX news

Loading headlines…

Financial statements

PTIX income statement

Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

PTIX: quick answers

What is PTIX's short interest?
As of October 30, 2026, 12,907 PTIX shares were sold short, down 0.3% from the count before. At the stock's average daily volume that is 6.6 days to cover. FINRA publishes the count twice a month. PTIX short interest history
ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.